Summary Background Cardiosphere-derived cells (CDCs) reduce scarring after myocardial
infarction, increase viable myocardium, and boost cardiac function in preclinical models. We …

Objectives: This study sought to report full 1-year results, detailed magnetic resonance
imaging analysis, and determinants of efficacy in the prospective, randomized, controlled …

Abstract Aims Cardiosphere-derived cells (CDCs) are cardiac progenitor cells that exhibit
disease-modifying bioactivity in various models of cardiomyopathy and in previous clinical …

Background—Cardiosphere-derived cells (CDCs) isolated from human endomyocardial
biopsies reduce infarct size and improve cardiac function in mice. Safety and efficacy testing …

Autologous cardiosphere-derived cells (CDCs) were the first therapeutic modality to
demonstrate myocardial regeneration with a decrease in scar size and an increase in viable …

Background—Intracoronary delivery of cardiosphere-derived cells (CDCs) has been
demonstrated to be safe and effective in porcine and human chronic myocardial infarction …

Background—SCIPIO is a first-in-human, phase 1, randomized, open-label trial of
autologous c-kit+ cardiac stem cells (CSCs) in patients with heart failure of ischemic etiology …

Background—Ex vivo expansion of resident cardiac stem cells, followed by delivery to the
heart, may favor regeneration and functional improvement. Methods and Results …

A decade ago, stem or progenitor cells held the promise of tissue regeneration in human
myocardium, with the expectation that these therapies could rescue ischemic myocyte …

Objectives: This study sought to compare the regenerative potency of cells derived from
healthy and diseased human hearts. Background: Results from pre-clinical studies and the …